Deuvacracitinib (Sotyktu), which the FDA approved in September 2022, is a first-of-its-class tyrosine kinase 2 inhibitor and a member of the Janus kinase family.
Warda Nawaz
Advertisement
Warda Nawaz, PharmD, is a medical writer based in Rancho Cordova, California.
Articles by Warda Nawaz
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
CHEST 2025: Brensocatib Shows Potential to Slow Structural Lung Changes in Bronchiectasis
2
Pharmacists Can Drive Equitable Diagnostics Access, Improve Antimicrobial Resistance Stewardship
3
From Stigma to Breakthrough: Psychedelic Medicine
4
Elinzanetant Reduces Frequency, Severity of VMS in Differing Female Populations
5
